1.上海市宝山区精神卫生中心(上海 201900)
2.上海交通大学医学院附属精神卫生中心(上海 201108)
3.上海中医药大学附属岳阳中西医结合医院(上海 200437)
李鸿,男,学士,主治医师,主要从事中西医结合精神医学临床研究
易正辉,教授、主任医师,博士生导师;E-mail: yizhenghui1971@163.com
吴嘉容,副主任医师;E-mail: wujiarong@126.com
扫 描 看 全 文
李鸿,吕钦谕,易正辉等.针刺治疗精神分裂症阴性症状临床疗效评价[J].上海中医药大学学报,2023,37(03):8-12.
LI Hong,LYU Qinyu,YI Zhenghui,et al.Clinical efficacy evaluation of acupuncture in treating negative symptoms of schizophrenia[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2023,37(03):8-12.
李鸿,吕钦谕,易正辉等.针刺治疗精神分裂症阴性症状临床疗效评价[J].上海中医药大学学报,2023,37(03):8-12. DOI: 10.16306/j.1008-861x.2023.03.002.
LI Hong,LYU Qinyu,YI Zhenghui,et al.Clinical efficacy evaluation of acupuncture in treating negative symptoms of schizophrenia[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2023,37(03):8-12. DOI: 10.16306/j.1008-861x.2023.03.002.
目的,2,探讨针刺治疗对精神分裂症患者阴性症状的疗效,为临床治疗提供依据。,方法,2,纳入100例以阴性症状为主的精神分裂症患者,采用随机数字表分为研究组和对照组,每组各50例。两组患者均给予氨磺必利片口服治疗,在此基础上,研究组患者给予针刺治疗,观察周期为12周。治疗前后,采用阳性与阴性症状量表(PANSS)、阴性症状量表(SANS)评价两组患者的精神分裂症阴性症状的改善情况。,结果,2,研究过程中,研究组4例患者剔除或脱落,最终纳入统计分析者研究组46例、对照组50例。治疗后,研究组患者的PANSS阴性症状、阳性症状、一般精神病理症状评分及总分较治疗前均明显降低(,P,<,0.01),对照组患者的阴性症状评分亦降低(,P,<,0.05),且研究组患者的阴性症状、一般精神病理症状评分及总分均明显低于对照组(,P,<,0.01)。治疗后,研究组患者的SANS各项评分较治疗前均明显降低(,P,<,0.01),对照组患者的各项评分与治疗前比较差异均无统计学意义(,P,>,0.05),且研究组患者的各项评分均低于对照组(,P,<,0.05,,P,<,0.01)。,结论,2,与单纯采用抗精神病药物治疗相比,针刺联合抗精神病药物能够更好地改善精神分裂症患者的阴性症状,具有一定的临床应用价值。
Objective: To explore the therapeutic effect of acupuncture on negative symptoms in patients with schizophrenia and provide the evidence for clinical treatment.,Methods,2,A total of 100 schizophrenic patients with negative symptoms were included and divided into the study group and control group by random number table, 50 cases in each group. The patients in both groups were orally treated with amsulpiride tablets. Based on above, the patients in the study group were treated with acupuncture. The observation period was 12 weeks. Before and after treatment, the positive and negative syndrome scale (PANSS) and scale for assessment of negative symptoms (SANS) were applied to evaluate the improvement of negative symptoms of schizophrenia in both groups.,Results,2,During the study, 4 patients in the study group were removed or shed off, and 46 patients in the study group and 50 patients in the control group were finally included in the statistical analysis. After treatment, the negative symptom, positive symptom, general psychopathological symptom scores and total score of PANSS in the study group were significantly decreased compared with those before treatment (,P,<,0.01), the negative symptom score in the control group was also decreased (,P,<,0.05), and the negative symptom, general psychopathological symptom scores and total score of the study group were significantly lower than those of the control group (,P,<,0.01). After treatment, the scores of all items of SANS in the study group were significantly decreased compared with those before treatment (,P,<,0.01), while there were no statistically significant differences on the scores of all items in the control group between before and after treatment (,P,>,0.05), and the scores of all items in the study group were lower than those in the control group (,P,<,0.05, ,P,<,0.01).,Conclusion,2,Compared with antipsychotic drugs alone, acupuncture combined with antipsychotic drugs can better improve the negative symptoms of patients with schizophrenia, which has certain clinical application value.
精神分裂症阴性症状针刺阳性与阴性症状量表
schizophrenianegative symptomsacupuncturepositive and negative syndrome scale
FERVAHA G, FOUSSIAS G, AGID O, et al. Impact of primary negative symptoms on functional outcomes in schizophrenia[J]. Eur Psychiatry, 2014, 29(7): 449-455.
LEPAGE M, BODNAR M, BOWIE C R. Neurocognition: clinical and functional outcomes in schizophrenia[J]. Can J Psychiatry, 2014, 59(1): 5-12.
DAVIS J M, CHEN N, GLICK I D. A meta-analysis of the efficacy of second-generation antipsychotics[J]. Arch Gen Psychiatry, 2003, 60(6): 553-564.
NIELSEN R E, LEVANDER S, KJAERSDAM TELLÉUS G, et al. Second-generation antipsychotic effect on cognition in patients with schizophrenia―a meta-analysis of randomized clinical trials[J]. Acta Psychiatr Scand, 2015, 131(3): 185-196.
世界卫生组织. ICD-10精神与行为障碍分类临床描述与诊断要点[M]. 北京: 人民卫生出版社, 1993: 72-74.
World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines[M]. Beijing: People’s Medical Publishing House, 1993: 72-74.
何燕玲, 张明园. 阳性和阴性症状量表的中国常模和因子分析[J]. 中国临床心理学杂志, 2000, 8(2): 65-69.
HE Y L, ZHANG M Y. Chinese norm and factor analysis of positive and negative syndrome scale [J]. Chinese Journal of Clinical Psychology, 2000, 8(2): 65-69.
张明园. 精神科评定量表手册[M]. 长沙: 湖南科学技术出版社, 1993.
ZHANG M Y. Psychiatric Rating Scale Manual [M]. Changsha: Hunan Science & Technology Press, 1993.
程小燕, 吕钦谕, 耿瑞杰, 等. 精神分裂症阴性症状的评估现状与面临的挑战[J]. 精神医学杂志, 2017, 30(2): 150-153.
CHENG X Y, LYU Q Y, GENG R J, et al. Assessment of negative symptoms in schizophrenia: Current status and challenges[J]. Journal of Psychiatry, 2017, 30(2): 150-153.
吕钦谕. 组胺H3受体在精神分裂症阴性症状和认知功能中的研究进展[J]. 复旦学报(医学版), 2021, 48(6): 834-840.
LYU Q Y. The progress on the effect of histaminergic H3 receptor on negative symptoms and cognitive function of schizophrenia[J]. Fudan University Journal of Medical Sciences, 2021, 48(6): 834-840.
SICRAS-MAINAR A, MAURINO J, RUIZ-BEATO E, et al. Impact of negative symptoms on healthcare resource utilization and associated costs in adult outpatients with schizophrenia: a population-based study[J]. BMC Psychiatry, 2014, 14: 225.
KANTROWITZ J T, EPSTEIN M L, LEE M, et al. Improvement in mismatch negativity generation during D-serine treatment in schizophrenia: Correlation with symptoms[J]. Schizophr Res, 2018, 191: 70-79.
D’SOUZA D C, CARSON R E, DRIESEN N, et al. Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects[J]. Biol Psychiatry, 2018, 84(6): 413-421.
MCCLURE M M, GRAFF F, TRIEBWASSER J, et al. Guanfacine augmentation of a combined intervention of computerized cognitive remediation therapy and social skills training for schizotypal personality disorder[J]. Am J Psychiatry, 2019, 176(4): 307-314.
KEM W R, OLINCY A, JOHNSON L, et al. Pharmacokinetic limitations on effects of an alpha7-nicotinic receptor agonist in schizophrenia: randomized trial with an extended-release formulation[J]. Neuropsychopharmacology, 2018, 43(3): 583-589.
TREGELLAS J R, WYLIE K P. Alpha7 nicotinic receptors as therapeutic targets in schizophrenia[J]. Nicotine Tob Res, 2019, 21(3): 349-356.
SHEKHAR A, POTTER W Z, LIGHTFOOT J, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia[J]. Am J Psychiatry, 2008, 165(8): 1033-1039.
SADEK B, SAAD A, SADEQ A, et al. Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases[J]. Behav Brain Res, 2016, 312: 415-430.
LEWEKE F M, MUELLER J K, LANGE B, et al. Role of the endocannabinoid system in the pathophysiology of schizophrenia: implications for pharmacological intervention [J]. CNS Drugs, 2018, 32(7): 605-619.
ÇAKICI N, VAN BEVEREN N J M, JUDGE-HUNDAL G, et al. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis[J]. Psychol Med, 2019, 49(14): 2307-2319.
DEAKIN B, SUCKLING J, DAZZAN P, et al. Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT[M]. Southampton (UK): NIHR Journals Library, 2019.
HUERTA-RAMOS E, LABAD J, COBO J, et al. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial[J]. Eur Arch Psychiatry Clin Neurosci, 2020, 270(6): 729-737.
李然然, 黑钢瑞, 杨叶, 等. 精神分裂症阴性症状及认知障碍增效治疗的研究进展[J]. 中南大学学报(医学版), 2020, 45(12): 1457-1463.
LI R R, HEI G R, YANG Y, et al. Research advances in add-on treatment for negative symptoms and cognitive dysfunction in schizophrenia [J]. Journal of Central South University (Medical Science), 2020, 45(12): 1457-1463.
SHEN X, XIA J, ADAMS C. Acupuncture for schizophrenia[J]. Schizophr Bull, 2014, 40(6): 1198-1199.
赵隽乔, 马铁明. 针灸治疗精神分裂症的Meta分析[J]. 针刺研究, 2018, 43(12): 806-812.
ZHAO J Q, MA T M. A Meta-analysis on Acupuncture and Moxibustion Treatment of Schizophrenia[J]. Acupuncture Research, 2018, 43(12): 806-812.
潘令仪, 沈含冰, 张佳宝, 等. 针灸对于精神分裂症缓解期患者生活质量的影响[J]. 世界中西医结合杂志, 2020, 15(4): 593-596.
PAN L Y, SHEN H B, ZHANG J B, et al. Effects of acupuncture and moxibustion on quality of life in patients with schizophrenia in remission[J]. World Journal of Integrated Traditional and Western Medicine, 2020, 15(4): 593-596.
张宏耕, 陈裕根, 宋炜熙, 等. 990例精神分裂症患者中医证候构成比分析[J]. 湖南中医药大学学报, 2011, 31(5): 57-59.
ZHANG H G, CHEN Y G, SONG W X, et al. Analysis of 990 patients with Schizophrenia on syndromes composition ratio in TCM[J]. Journal of Traditional Chinese Medicine University of Hunan, 2011, 31(5): 57-59.
刘波, 华婷婷, 赵媛媛, 等. 精神分裂症不同中医辨证分型患者精神症状与认知功能的相关性[J]. 新乡医学院学报, 2018, 35(4): 298-302.
LIU B, HUA T T, ZHAO Y Y, et al. Associativity of psychiatric symptom and cognitive function in schizophrenic patients with different types of traditional Chinese medicine[J]. Journal of Xinxiang Medical University, 2018, 35(4): 298-302.
段冬梅, 图娅, 陈利平. 电针不同穴组对抑郁大鼠行为活动及海马p-CREB表达的影响[J]. 中国针灸, 2008, 28(5): 369-373.
DUAN D M, TU Y, CHEN L P. Effects of electroacupuncture at different acupoint groups on behavior activity and p-CREB expression in hippocampus in the rat of depression[J]. Chinese Acupuncture & Moxibustion, 2008, 28(5): 369-373.
0
浏览量
76
下载量
0
CSCD
0
CNKI被引量
关联资源
相关文章
相关作者
相关机构